Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/10/2010

riod in 2008. For the year ended December 31, 2009, research and development expenses were $0.5 million, compared to $0.4 million in 2008. The increase in research and development expense was primarily due to certain employee costs, which were reimbursable under the Company's agreement with DFB Biotech, Inc. and its affiliates ("DFB") until October 2008 and stock-based compensation expense partially offset by decreases in external study development costs.

General and administrative expenses for the fourth quarter of 2009 and 2008 were essentially unchanged at $1.3 million. For the year ended December 31, 2009, general and administrative expenses were $4.8 million, compared to $4.2 million in 2008. The increase in general and administrative expenses were primarily due to outside consulting services, certain facility costs which were reimbursable under the DFB agreement until October 2008, employee costs, legal fees and board member service partially offset by a decrease in patent related fees and stock-based compensation expense.

As of December 31, 2009, BioSpecifics held cash, cash equivalents and investments of $8.5 million, compared to $4.4 million on December 31, 2008'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... MENLO PARK, Calif. , April 1, 2015 ... ("DelMar" and the "Company"), today announced that it has ... R.Psych., to its Board of Directors as an independent ... decades of biotechnology experience in executive leadership roles as ... member, including serving as the chairman of a leading ...
(Date:3/31/2015)... , March 31, 2015 Neurocrine Biosciences, Inc. ... entered into an exclusive collaboration and licensing agreement for ... in Japan and other select ... Mitsubishi Tanabe intends to initially develop NBI-98854 in ... Huntington,s disease and tardive dyskinesia. Neurocrine retains full commercial ...
(Date:3/31/2015)... , March 31, 2015 ... the multidisciplinary confocal laser endomicroscopy platform, today announced the ... de Grenoble (university hospital center). The CHU de Grenoble ... to propose to its gastroenterology, interventional pulmonology ... and a higher standard of care thanks to the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 2DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 3DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 4Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 2Grenoble University Hospital First Hospital in France to set up a Multidisciplinary Optical Biopsy Program With the Cellvizio Endomicroscopy Platform 3
... Reportlinker.com announces that a new market research report is available ... http://www.reportlinker.com/p0324750/Virtual-Pharma.html ... in the pharmaceutical market has slowed – almost to a ... cutting costs in a faltering world economy. ...
... NEW YORK, Nov. 3, 2010 Pfizer Inc. (NYSE: ... public to view and listen to a webcast of ... Primary Care, at the 2010 Annual Credit Suisse Healthcare ... Mountain Standard Time. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Reportlinker Adds Virtual Pharma 2Reportlinker Adds Virtual Pharma 3Reportlinker Adds Virtual Pharma 4Reportlinker Adds Virtual Pharma 5Reportlinker Adds Virtual Pharma 6
(Date:4/1/2015)... When annoying or concerning skin conditions such as ... an appointment with a dermatologist is the last thing ... been possible within dermatology. However, in the Sheboygan and ... for this level of service and are answering consumer’s ... answers to dermatological issues are to our patients, and ...
(Date:4/1/2015)... Atlanta, GA (PRWEB) April 01, 2015 ... Emergency Medicine Practice, Pediatric Emergency Medicine Practice, and ... it has partnered with AgileMD to provide the ... Practice , in a mobile application format available ... , “Our collaboration with AgileMD to develop ...
(Date:4/1/2015)... 01, 2015 On May 1, 2015, the ... annual Educational Institute in Albany, New York . This ... in nursing and feature an address by Helen R. Connors, ... Professor, University of Kansas School of Nursing and Center for ... being sponsored by the Excelsior College School of Nursing, ...
(Date:4/1/2015)... It is the meat that has become an ... wrapped around other foods, infused into cocktails and even made ... the gateway meat for vegetarians and the perfect food. To ... Meat Institute (NAMI) has developed a new Ultimate Guide ... bacon processing plant and companion brochure with ...
(Date:4/1/2015)... 2015 Natural fertility experts from around ... the world’s first Integrative Fertility Symposium ( https://ifsymposium.com/ ) ... (SFU Downtown Campus), 515 West Hastings Street, Vancouver BC. ... May 3rd, 3:00 pm to 5:00 pm at Harbour ... of its kind in the world to bring together ...
Breaking Medicine News(10 mins):Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 2Health News:EB Medicine Partners With AgileMD on Mobile Application for Emergency Medicine Clinicians 3Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 2Health News:Excelsior College School of Nursing Educational Institute to Influence Nursing Empowerment 3Health News:New Ultimate Guide to Bacon Video Provides Inside Look at How Bacon is Made 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 3
... Health Care Reform, Importance of Achieving,Quality in Medicine During ... State and national leaders,focused on health care reform ... care today at the 2007 Georgia Health Care Symposium,held ... and policy leaders attended the event, which was hosted ...
... 26 Today, at the annual,conference of the ... America, along with the Colorado Springs Police Department,announced ... to raise awareness and reduce demand for the ... Meth360(R), was created by the Partnership, and is,currently ...
... attacks cancer in an entirely new way has shown ... disease and prolonging the lives of patients. , New ... (ECCO 14) in Barcelona found that giving the new ... amount of time patients survived without progression of their ...
... 26 Biomedtex Inc.,(Pink Sheets: PDNL.PK) ("Biomed" or ... that A. Marc Rocca, 42, will be,President and ... mission is to identify, evaluate and assess a ... and then,seek to capture and promote innovations with ...
... Nycomed Acquires Exclusive Rights Outside North America in Deal Valued ... ... N.J. and ZURICH, Switzerland, Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: ... into a definitive agreement,which licenses to Nycomed the rights to ...
... Spain: New research has yielded a clearer picture of ... treatment of colon cancer, bringing closer the day when ... it, while those that will, get the more aggressive ... solid tumours, doctors plan treatment of colon cancer chiefly ...
Cached Medicine News:Health News:Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care 2Health News:Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care 3Health News:Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement 2Health News:Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement 3Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
... Fast-Cath, Maximum, Maximum Xtra, and ... line of standard and specialty hemostasis ... recognized as the premier hemostasis introducers ... electrophysiology procedures including angiography, angioplasty, stenting, ...
Medicine Products: